Ironwood Pharmaceuticals Cash on Hand 2012-2025 | IRWD

Ironwood Pharmaceuticals cash on hand from 2012 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Ironwood Pharmaceuticals Annual Cash on Hand
(Millions of US $)
2024 $89
2023 $92
2022 $657
2021 $621
2020 $364
2019 $178
2018 $174
2017 $221
2016 $305
2015 $439
2014 $248
2013 $198
2012 $168
2011 $164
Ironwood Pharmaceuticals Quarterly Cash on Hand
(Millions of US $)
2025-09-30 $140
2025-06-30 $93
2025-03-31 $108
2024-12-31 $89
2024-09-30 $88
2024-06-30 $106
2024-03-31 $122
2023-12-31 $92
2023-09-30 $111
2023-06-30 $176
2023-03-31 $742
2022-12-31 $657
2022-09-30 $575
2022-06-30 $506
2022-03-31 $595
2021-12-31 $621
2021-09-30 $576
2021-06-30 $494
2021-03-31 $440
2020-12-31 $364
2020-09-30 $309
2020-06-30 $255
2020-03-31 $232
2019-12-31 $178
2019-09-30 $147
2019-06-30 $107
2019-03-31 $120
2018-12-31 $174
2018-09-30 $161
2018-06-30 $181
2018-03-31 $194
2017-12-31 $221
2017-09-30 $225
2017-06-30 $273
2017-03-31 $297
2016-12-31 $305
2016-09-30 $320
2016-06-30 $325
2016-03-31 $435
2015-12-31 $439
2015-09-30 $462
2015-06-30 $493
2015-03-31 $216
2014-12-31 $248
2014-09-30 $265
2014-06-30 $302
2014-03-31 $332
2013-12-31 $198
2013-09-30 $242
2013-06-30 $301
2013-03-31 $242
2012-12-31 $168
2012-09-30 $193
2012-06-30 $158
2012-03-31 $202
2011-12-31 $164
2011-09-30 $175
2011-06-30 $201
2011-03-31 $221
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.745B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $84.909B 32.25
Zoetis (ZTS) United States $54.311B 19.44
Takeda Pharmaceutical (TAK) Japan $51.389B 10.49
Daiichi Sankyo, - (DSNKY) Japan $38.891B 19.37
BeOne Medicines - (ONC) Switzerland $36.658B 194.35
Sandoz Group AG (SDZNY) Switzerland $33.832B 0.00
United Therapeutics (UTHR) United States $20.154B 17.74
Merck (MKKGY) Germany $19.005B 11.72
Shionogi (SGIOY) Japan $15.636B 14.36
Neurocrine Biosciences (NBIX) United States $13.414B 32.19
IPSEN (IPSEY) France $12.891B 0.00
Ionis Pharmaceuticals (IONS) United States $12.558B 0.00
Summit Therapeutics (SMMT) United States $12.385B 0.00
Madrigal Pharmaceuticals (MDGL) United States $11.468B 0.00
Orion OYJ (ORINY) Finland $10.204B 29.15
Eisai (ESAIY) $8.120B 0.00
Ono Pharmaceutical (OPHLF) Japan $6.967B 21.19
Grifols, S.A (GRFS) Spain $5.940B 0.00
Stevanato Group S.p.A (STVN) Italy $5.784B 32.37
Crinetics Pharmaceuticals (CRNX) United States $5.285B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.613B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.190B 19.90
Indivior (INDV) United States $4.119B 16.81
Corcept Therapeutics (CORT) United States $3.712B 40.10
NewAmsterdam Pharma (NAMS) Netherlands $3.675B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $3.081B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.874B 9.17
Hypermarcas (HYPMY) Brazil $2.755B 18.91
Ocular Therapeutix (OCUL) United States $2.439B 0.00
Dyne Therapeutics (DYN) United States $2.368B 0.00
Soleno Therapeutics (SLNO) United States $2.349B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $2.100B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.950B 23.11
Ardelyx (ARDX) United States $1.885B 0.00
Amylyx Pharmaceuticals (AMLX) United States $1.818B 0.00
Guardian Pharmacy Services (GRDN) United States $1.793B 34.54
Harrow (HROW) United States $1.767B 108.46
Oruka Therapeutics (ORKA) United States $1.609B 0.00
Enliven Therapeutics (ELVN) United States $1.605B 0.00
Collegium Pharmaceutical (COLL) United States $1.508B 7.46
BioCryst Pharmaceuticals (BCRX) United States $1.406B 83.38
Relay Therapeutics (RLAY) United States $1.284B 0.00
Xeris Biopharma Holdings (XERS) United States $1.263B 0.00
Savara (SVRA) United States $1.215B 0.00
Evotec AG (EVO) Germany $1.204B 0.00
Theravance Biopharma (TBPH) United States $1.035B 43.45
ARS Pharmaceuticals (SPRY) United States $1.033B 0.00
Cronos Group (CRON) Canada $0.973B 0.00
Aktis Oncology (AKTS) United States $0.951B 0.00
Xencor (XNCR) United States $0.903B 0.00
KalVista Pharmaceuticals (KALV) United States $0.774B 0.00
Nektar Therapeutics (NKTR) United States $0.737B 0.00
Esperion Therapeutics (ESPR) United States $0.691B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.660B 5.89
ProKidney (PROK) United States $0.644B 0.00
Bioventus (BVS) United States $0.638B 13.07
Lexeo Therapeutics (LXEO) United States $0.530B 0.00
Zevra Therapeutics (ZVRA) United States $0.508B 0.00
Lyell Immunopharma (LYEL) United States $0.508B 0.00
Elite Pharmaceuticals (ELTP) United States $0.505B 0.00
Aclaris Therapeutics (ACRS) United States $0.480B 0.00
Organogenesis (ORGO) United States $0.471B 0.00
Siga Technologies (SIGA) United States $0.468B 6.41
Altimmune (ALT) United States $0.441B 0.00
4D Molecular Therapeutics (FDMT) United States $0.435B 0.00
Aquestive Therapeutics (AQST) United States $0.425B 0.00
Nature's Sunshine Products (NATR) United States $0.418B 24.91
USANA Health Sciences (USNA) United States $0.402B 11.21
Cybin (HELP) Canada $0.383B 0.00
Akebia Therapeutics (AKBA) United States $0.356B 0.00
Achieve Life Sciences (ACHV) Canada $0.292B 0.00
Protara Therapeutics (TARA) United States $0.289B 0.00
Relmada Therapeutics (RLMD) United States $0.289B 0.00
Profound Medical (PROF) Canada $0.286B 0.00
Aldeyra Therapeutics (ALDX) United States $0.286B 0.00
Avalo Therapeutics (AVTX) United States $0.274B 0.00
OmniAb (OABI) United States $0.274B 0.00
Larimar Therapeutics (LRMR) United States $0.265B 0.00
Fractyl Health (GUTS) United States $0.262B 0.00
Heron Therapeutics (HRTX) United States $0.260B 0.00
Silence Therapeutics (SLN) United Kingdom $0.246B 0.00
Journey Medical (DERM) United States $0.237B 0.00
Enlivex Therapeutics (ENLV) Israel $0.233B 0.00
MediWound (MDWD) Israel $0.218B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.207B 0.00
Galectin Therapeutics (GALT) United States $0.193B 0.00
Minerva Neurosciences (NERV) United States $0.189B 0.00
AleAnna (ANNA) United States $0.183B 0.00
Innate Pharma SA (IPHYF) France $0.181B 0.00
Century Therapeutics (IPSC) United States $0.168B 0.00
VAXART, INC (VXRT) United States $0.166B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.161B 0.00
Surrozen (SRZN) United States $0.154B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.151B 0.00
Context Therapeutics (CNTX) United States $0.141B 0.00
Unicycive Therapeutics (UNCY) United States $0.141B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.127B 0.00
Inhibikase Therapeutics (IKT) United States $0.124B 0.00
Incannex Healthcare (IXHL) Australia $0.124B 0.00
Prelude Therapeutics (PRLD) United States $0.116B 0.00
Avita Medical (RCEL) United States $0.115B 0.00
Karyopharm Therapeutics (KPTI) United States $0.109B 0.00
Pyxis Oncology (PYXS) United States $0.103B 0.00
Cardiol Therapeutics (CRDL) Canada $0.101B 0.00
Vivani Medical (VANI) United States $0.099B 0.00
Champions Oncology (CSBR) United States $0.097B 41.18
Cassava Sciences (SAVA) United States $0.096B 0.00
Korro Bio (KRRO) United States $0.081B 0.00
Gain Therapeutics (GANX) United States $0.077B 0.00
Assertio Holdings (ASRT) United States $0.075B 0.00
PolyPid (PYPD) Israel $0.071B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.071B 59.00
Dominari Holdings (DOMH) United States $0.067B 0.00
NRx Pharmaceuticals (NRXP) United States $0.065B 0.00
Arch Biopartners (ACHFF) Canada $0.064B 0.00
Rafael Holdings (RFL) United States $0.063B 0.00
Acrivon Therapeutics (ACRV) United States $0.062B 0.00
Metagenomi (MGX) United States $0.060B 0.00
PMV Pharmaceuticals (PMVP) United States $0.057B 0.00
Nutriband (NTRB) United States $0.056B 0.00
Lipocine (LPCN) United States $0.055B 0.00
ElectroCore (ECOR) United States $0.055B 0.00
Lite Strategy (LITS) United States $0.048B 0.00
Talphera (TLPH) United States $0.046B 0.00
Telomir Pharmaceuticals (TELO) United States $0.046B 0.00
Plus Therapeutics (PSTV) United States $0.040B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.039B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.035B 0.00
Wellgistics Health (WGRX) United States $0.035B 0.00
Jupiter Neurosciences (JUNS) United States $0.031B 0.00
Natural Alternatives (NAII) United States $0.030B 0.00
TherapeuticsMD (TXMD) United States $0.029B 0.00
SCYNEXIS (SCYX) United States $0.027B 0.00
Klotho Neurosciences (KLTO) United States $0.023B 0.00
Traws Pharma (TRAW) United States $0.021B 0.03
Scienture Holdings (SCNX) United States $0.020B 0.00
Liminatus Pharma (LIMN) United States $0.020B 0.00
VYNE Therapeutics (VYNE) United States $0.019B 0.00
Inotiv (NOTV) United States $0.019B 0.00
Vivos Therapeutics (VVOS) United States $0.019B 0.00
Cosmos Health (COSM) United States $0.019B 0.00
Iterum Therapeutics (ITRM) Ireland $0.018B 0.00
Citius Pharmaceuticals (CTXR) United States $0.017B 0.00
Vyome Holdings (HIND) United States $0.016B 0.00
Mannatech (MTEX) United States $0.014B 0.00
Tempest Therapeutics (TPST) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.012B 0.00
CASI Pharmaceuticals (CASI) China $0.012B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
China SXT Pharmaceuticals (SXTC) China $0.011B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.011B 0.00
Addex Therapeutics (ADXN) Switzerland $0.010B 0.00
Mangoceuticals (MGRX) United States $0.010B 0.00
Ernexa Therapeutics (ERNA) United States $0.010B 0.00
BioVie (BIVI) United States $0.009B 0.00
Ainos (AIMD) United States $0.009B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.009B 0.00
Nuvilex (PMCB) United States $0.009B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Heatwurx (PCSA) United States $0.007B 0.00
Alaunos Therapeutics (TCRT) United States $0.007B 0.00
Redhill Biopharma (RDHL) Israel $0.007B 0.00
Aptorum Group (APM) United Kingdom $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
Lyra Therapeutics (LYRA) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
CDT Equity (CDT) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00